<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04766502</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A00645-36</org_study_id>
    <nct_id>NCT04766502</nct_id>
  </id_info>
  <brief_title>Bonds Between Circulating Tumoral ADN (ctDNA) and the Development of Peritoneal Carcinomatosis for Patients Under PIPAC</brief_title>
  <acronym>PIPADN</acronym>
  <official_title>Study Evaluating the Bonds Between Circulating Tumoral ADN (ctDNA) and the Development of Peritoneal Carcinomatosis for Patients Treated With PIPAC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PIPADN is a pilot monocentric, study with a total duration of 42 months. The purpose of this&#xD;
      study is to describe the variation of plasma ctDNA concentration between the 1st and the 3rd&#xD;
      PIPAC session in patients with peritoneal carcinomatosis.&#xD;
&#xD;
      The improvement of life quality with this type of treatment will also be evaluated though the&#xD;
      EORTC QLQ-C30 survey.&#xD;
&#xD;
      Each patient will have three PIPAC sessions spaced 6 to 8 weeks apart. Two blood samples will&#xD;
      be taken during the first 3 PIPAC sessions, one the day before each procedure and a second&#xD;
      one 24 hours afterwards.&#xD;
&#xD;
      The EORTC QLQ 30 survey will be completed by patients during the pre-operative consultation&#xD;
      and at each post-operative consultation (about 3 weeks after PIPAC sessions).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ctDNA</measure>
    <time_frame>change from inclusion at 12 weeks</time_frame>
    <description>ctDNA concentration change (ng/mL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peritoneal Regression Grading Score (PRGS)</measure>
    <time_frame>at inclusion</time_frame>
    <description>Results of each PIPAC will be evaluated using PRGS. PRGS (Peritoneal Regression Grading Score), going from 1 : no tumor cells, to 4 :solid growth in tumor cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peritoneal Regression Grading Score (PRGS)</measure>
    <time_frame>an average of 6 weeks</time_frame>
    <description>Results of each PIPAC will be evaluated using PRGS. PRGS : (Peritoneal Regression Grading Score), going from 1 : no tumor cells, to 4 :solid growth in tumor cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peritoneal Regression Grading Score (PRGS)</measure>
    <time_frame>an average of 12 weeks</time_frame>
    <description>Results of each PIPAC will be evaluated using PRGS. PRGS (Peritoneal Regression Grading Score), going from 1 : no tumor cells, to 4 :solid growth in tumor cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PIPAC discontinuation</measure>
    <time_frame>an average of 6 week</time_frame>
    <description>The reason (ei : progression, deterioration of the patient's general condition) of PIPAC discontinuation for patient who have had less than 3 PIPAC sessions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PIPAC discontinuation</measure>
    <time_frame>an average of 12 weeks</time_frame>
    <description>The reason (ei : progression, deterioration of the patient's general condition) of PIPAC discontinuation for patient who have had less than 3 PIPAC sessions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peritoneal cancer index mesure</measure>
    <time_frame>at inclusion</time_frame>
    <description>Evaluation of disease extent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peritoneal cancer index mesure</measure>
    <time_frame>an average of 6 week</time_frame>
    <description>Evaluation of disease extent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peritoneal cancer index mesure</measure>
    <time_frame>an average of 12 weeks</time_frame>
    <description>Evaluation of disease extent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life mesure</measure>
    <time_frame>At inclusion</time_frame>
    <description>Quality of life will be mesured by EORTC Quality of Life C30 survey. EORTC : European Organization for Research and Treatment of Cancer. Measured from 0 to 35, 0 meaning minimal mictionnal discomfort, 35 meaning maximal mictionnal discomfort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life mesure</measure>
    <time_frame>an average of 3 weeks</time_frame>
    <description>Quality of life will be mesured by EORTC Quality of Life C30 survey. EORTC : European Organization for Research and Treatment of Cancer. Measured from 0 to 35, 0 meaning minimal mictionnal discomfort, 35 meaning maximal mictionnal discomfort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life mesure</measure>
    <time_frame>an average of 9 weeks</time_frame>
    <description>Quality of life will be mesured by EORTC Quality of Life C30 survey. EORTC : European Organization for Research and Treatment of Cancer. Measured from 0 to 35, 0 meaning minimal mictionnal discomfort, 35 meaning maximal mictionnal discomfort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life mesure</measure>
    <time_frame>an average of 15 weeks</time_frame>
    <description>Quality of life will be mesured by EORTC Quality of Life C30 survey. EORTC : European Organization for Research and Treatment of Cancer. Measured from 0 to 35, 0 meaning minimal mictionnal discomfort, 35 meaning maximal mictionnal discomfort</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Peritoneal Carcinomatosis</condition>
  <arm_group>
    <arm_group_label>Blood sample (20ml) and Quality of Life Survey</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample (20 ml) and EORTC QLQC30 survey</intervention_name>
    <description>Blood sample (20ml) will be taken before and 24h after PIPAC procedure&#xD;
EORTC QLQC30 during pre operative consultation and at each post operative consultations</description>
    <arm_group_label>Blood sample (20ml) and Quality of Life Survey</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years old&#xD;
&#xD;
          -  WHO 0 to 2&#xD;
&#xD;
          -  Patient with cancer in the form of peritoneal carcinosmatois not eligible for&#xD;
             cytoreduction surgery&#xD;
&#xD;
          -  A histological diagnosis of the primary tumor or peritoneal carcinomatosis is&#xD;
             essential.&#xD;
&#xD;
          -  Patient with an indication for PIPAC for any reason (whether as part of a clinical&#xD;
             research protocol or not). Patients with prior treatment with PIPAC are eligible.&#xD;
&#xD;
          -  Patients with abdominal metastases or a single metastasis regardless of location&#xD;
             (oligometastasis).&#xD;
&#xD;
          -  For patients of childbearing age need for an effective method of contraception&#xD;
&#xD;
          -  Informing patients and obtaining informed consent, dated and signed.&#xD;
&#xD;
          -  Patient affiliated with a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years old&#xD;
&#xD;
          -  WHO &gt; 3&#xD;
&#xD;
          -  Patient who may benefit from cytoreduction surgery&#xD;
&#xD;
          -  Patient with a contraindication to PIPAC&#xD;
&#xD;
          -  Extra peritoneal disease with the exception of oligometastatic disease&#xD;
&#xD;
          -  Persons deprived of liberty or under guardianship (including curatorship)&#xD;
&#xD;
          -  Impossibility to undergo the medical follow-up of the trial for social, geographical&#xD;
             or psychological reasons.&#xD;
&#xD;
          -  For patients of childbearing age without an effective method of contraception&#xD;
&#xD;
          -  Woman who is pregnant, likely to be pregnant, or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cécilia CERIBELLI, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean Louis MERLIN, PU PH</last_name>
    <phone>03 83 65 60 62</phone>
    <phone_ext>0033</phone_ext>
    <email>jl.merlin@nancy.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marie-Aude HERMAN</last_name>
    <phone>03 83 53 86 68</phone>
    <phone_ext>0033</phone_ext>
    <email>m.herman@nancy.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Cécilia CERIBELLI, MD</last_name>
      <phone>03 83 59 84 51</phone>
      <phone_ext>0033</phone_ext>
      <email>c.ceribelli@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 9, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PIPAC</keyword>
  <keyword>Peritoneal Carcinomatosis</keyword>
  <keyword>Circulating tumour DNA</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

